Eli Lilly (LLY) is one step closer to getting its new Alzheimer's treatment approved by the Food and Drug Administration (FDA) after a panel voted to recommend its use. BMO Capital Markets ...
Eli Lilly’s revenue has taken off thanks to two of its drugs that doctors prescribe for weight loss. The company also has a full portfolio of other products, and some increased revenue in the ...
Eli Lilly (LLY) is riding high on its diabetes and weight-loss treatments Mounjaro and Zepbound — which Wall Street estimates could net the company $13.5 billion in 2024. "It's not just a flash ...
Eli Lilly's stock has seen significant gains due to the success of its GLP-1 franchise and the potential of donanemab for Alzheimer's disease. The FDA's Advisory Committee endorsed donanemab for ...
A Food and Drug Administration advisory panel on Monday endorsed the experimental Alzheimer's drug donanemab, which studies showed slowed early stages of the fatal mind-robbing disease. The ...
20-year-old charged for allegedly jumping 78-year-old man with dementia, police say Olive oil may lower your risk of dementia ...
Glencar has taken over the construction of a life sciences building near Cambridge from collapsed contractor Readie. Readie ...
, opens new tab late stage trial on experimental obesity pill orforglipron is expected in April 2025, a top Eli Lilly (LLY.N) , opens new tab executive said on Monday. The pill is part of a class ...
The incident comes after a series of official investigations last year related to the issuance of fake birth certificates at a time when China is trying to boost its birth rate. Cardinal now expects ...